Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years.

@article{Klonoff2008ExenatideEO,
  title={Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years.},
  author={David C. Klonoff and John B Buse and Loretta L. Nielsen and Xuesong Guan and Christopher L Bowlus and John H. Holcombe and Matthew E Wintle and David Maggs},
  journal={Current medical research and opinion},
  year={2008},
  volume={24 1},
  pages={275-86}
}
BACKGROUND Exenatide, an incretin mimetic for adjunctive treatment of type 2 diabetes (T2DM), reduced hemoglobin A(1c) (A1C) and weight in clinical trials. The objective of this study was to evaluate the effects of > or = 3 years exenatide therapy on glycemic control, body weight, cardiometabolic markers, and safety. METHODS Patients from three placebo-controlled trials and their open-label extensions were enrolled into one open-ended, open-label clinical trial. Patients were randomized to… CONTINUE READING
Highly Influential
This paper has highly influenced 32 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
304 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 304 extracted citations

Similar Papers

Loading similar papers…